
0:00
13:06
Surprisingly (unbelievably?) impressive RCT evaluating the Blys/APRIL inhibitor "telitacicept" for patients with SLE (mixed SLE and SLE-LN). Very curious to see where the FDA goes with this one.
Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2414719
More episodes from "The Evidence Based Rheumatology Podcast"



Don't miss an episode of “The Evidence Based Rheumatology Podcast” and subscribe to it in the GetPodcast app.







